PFE · Pfizer Inc
Price
Snapshot
50 fields · last close| Market Cap | $168.6B |
| P/E | 38.91 |
| Float | 5.69B |
| Beta | 0.31 |
| Volatility | 7.7% |
| Exchange | NYSE |
| Sector | Pharmaceuticals |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 83.7 |
| Price | 29.43 |
| Change | −0.51% |
| Prev Close | 29.58 |
| Open | 29.72 |
| Day Low | 29.42 |
| Day High | 29.74 |
| Avg Vol | 30 |
| Avg $ Vol | $894.0M |
| 52W High | 29.88 |
| 52W Low | 23.62 |
| 52W Pos | 92.8% |
| From High | −1.51% |
| From Low | +24.60% |
| Max DD 1Y | −17.09% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | +3.84% |
| SMA 50 | +5.22% |
| SMA 200 | +10.79% |
| RSI (14) | 69.7 |
| Vol 30D | 16.9% |
| Vol 90D | 20.8% |
| 1Y Range | 24–30 |
| Daily bars | 536 |
| Perf Week | +4.60% |
| Perf Month | +7.02% |
| Perf Quarter | +19.52% |
| Perf Half Y | +7.33% |
| Perf Year | +21.28% |
| Perf YTD | +16.88% |
| Prev Day | −0.51% |
| Clavix | A- |
| Debt / Eq | 0.05 |
| Curr Ratio | 1.16 |
| Int Cover | 5.4× |
| FCF Margin | 14.5% |
| Rev Growth | −1.6% |
| Profit | Profitable |
| Leverage | Moderate |
| Sector rank | 2 / 14 |
What PFE does
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19.
It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands.
In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands.
Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin.
The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models.
Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Clavix risk grade
regraded every trading dayPFE grades A-, 83.7 of 100. Steadiest on Macro Resilience (72), most exposed on News Sentiment (53, mixed). 3 of the 4 weighted dimensions sit above the Pharmaceuticals median. Ranks 2 of 14 in Pharmaceuticals by Clavix score.
How rough the ride is
| PFE | Pharmaceuticals median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.31 | 0.44 |
| Volatilityannualized | 7.7% | 10.9% |
| Max drawdown, past yearworst peak-to-trough fall | −17.1% | — |
| Typical daily movemedian absolute daily change | 0.87% | — |
| Days beyond ±3%of the last 252 sessions | 7 (3%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| PFE | Pharmaceuticals median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.31 | 0.44 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low 67% of 15 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Pharmaceuticals names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| PFE | |
|---|---|
| 1 week | +4.6% |
| 1 month | +7.0% |
| Year to date | +16.9% |
| 1 year | +21.3% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| PFE | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 1 Oct |
| Average score0 most bearish, 100 most bullish | 51 |
| Bullish · bearisharticles above 60 · below 40 | 13 · 10 |
| Directionarticles whose tone is improving vs worsening | 13 ↑ 10 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 15 Pharmaceuticals names Clavix covers; the tick is the sector median.
Growth
| PFE | |
|---|---|
| Revenue growthyear over year | −1.6% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Pharmaceuticals median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openPfizer has frozen its dividend, and while its 5.8% yield looks attractive, the dividend is eating up more of the company's cash generation than the headline numbers suggest, raising questions about how sustainable the payout actually is.
Pfizer declared its 352nd consecutive quarterly dividend, currently yielding about 6%. The article notes the company faces significant patent cliffs this year and next, but also has a robust pipeline of new drugs in development.
Pfizer declared a $0.43 fourth-quarter dividend, its 352nd consecutive quarterly payment, giving an annual rate of $1.72 per share and a yield of roughly 5.9%. The article raises the question of whether that payout is sustainable, noting that Pfizer halved its dividend in 2009 but has raised it every year since 2010.
Pfizer won expanded FDA approval for its drug TUKYSA as a chemotherapy-free maintenance treatment for HER2-positive metastatic breast cancer (a breast cancer that has spread and carries a specific protein). It also reported late-stage trial results for vaccines targeting Lyme disease, pneumococcal disease, and RSV.
A short roundup article asks why shares of GME, BMBL, and PFE each hit new 52-week highs. It lists insider purchases, a multibillion-dollar acquisition, and progress in vaccine research as the drivers behind the moves without clearly tying each driver to a specific company.
Nearest peers by size
Pharmaceuticals| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| AZN | AstraZeneca PLC | B+ | $196.9B | 25.12 | 1.27 | Compare |
| BMY | Bristol-Myers Squibb Co | B+ | $122.1B | 13.15 | 0.19 | Compare |
| MRK | Merck & Co Inc | B+ | $360.1B | 113.48 | 0.12 | Compare |
| JNJ | Johnson & Johnson | A- | $615.9B | 38.26 | 0.21 | Compare |
| RPRX | Royalty Pharma PLC | A | $35.06B | 43.01 | 0.39 | Compare |
| ZTS | Zoetis Inc | B+ | $31.87B | 12.55 | 0.70 | Compare |
| LLY | Eli Lilly and Co | B | $1.18T | 44.30 | 0.42 | Compare |
| VTRS | Viatris Inc | B+ | $21.43B | — | 0.89 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.